Roivant Sciences
As of the edition of 20 October 2026, Roivant Sciences runs 4 drugs, 1 of them marketed; it is on route A at 1 target and on route B at 2 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 5 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 2 |
| Stopped | 1 |
| Total | 4 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Brepocitinib | none listed | 3 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 2 targets.
All 3 rows on route A or B
In the product3 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 3 targets where Roivant Sciences needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Immune system: 17 trials led
- Eye: 11 trials led
- Hormones: 9 trials led